Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

Completed · Phase 4 · Has a placebo group

Conditions studied: Myomectomy; Surgical Blood Loss

In brief

Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss when compared to vasopressin alone, which is our current practice at this time. The study will be double-blinded with neither the patient nor the researcher knowing whether the placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and hematocrit, need for transfusion, and operative time among other measures of perioperative morbidity to see if the addition of misoprostol makes a significant difference. We will also observe patients to see if there are any side effects of misoprostol that make its use undesirable.

Key facts

Study ID

NCT03064568

Run by

The University of Texas Health Science Center at San Antonio

People needed

18

Starts

2016-10-14

Expected to finish

2024-06-18

Last updated by the study team

2025-07-29

Who can join

Age: 20 and older, up to 50. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Female age 20-50 y/o who plan to undergo abdominal myomectomy for symptomatic myomatous uterus

You may not qualify if…

• Patient with contraindication to misoprostol or vasopressin, personal history or cardiac or pulmonary disease, history of prior myomectomy

Where it is running

• St. Lukes Baptist Hospital — San Antonio, Texas, United States
• University Hospital — San Antonio, Texas, United States
• University of Texas Health Science Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.